Private Placement

StickIt Technologies bets on a complex share consolidation and capital raise to survive, but are the terms a red flag for its investors and future?

Genelux appoints Dr. Jason Litten as CMO, a strategic move to steer its promising oncolytic virus, Olvi-Vec, through crucial late-stage cancer trials.

Intelligent Bio Solutions raised crucial capital for its fingerprint drug test, but the deal's structure sent shares tumbling amid shareholder dilution fears.

The junior explorer has raised crucial capital to advance its drilling programs in Quebec's prolific gold belt, signaling strong investor confidence.

Cannabix Technologies lands its first international order for its smart breathalyzer in Australia, a move that validates its tech and reshapes its finances.

reAlpha Mortgage is offering stock ownership and AI assistants to attract loan officers, a move that could disrupt traditional industry compensation.

Euromax Resources raised C$1.6M, but with 84% for overhead and only 9% for its stalled gold project, is this a step forward or just staying afloat?

Esports giant OverActive Media is raising fresh capital. Is this a strategic push into AI and esports dominance or a necessary move to shore up its finances?

Facing a Nasdaq delisting threat, China-based WF International has 180 days to revive its stock after a dramatic collapse since its April IPO.

Profound Medical raises over $42M to advance its AI-powered, incision-free therapies for cancer and other diseases, signaling strong investor confidence.

A strategic alliance surpassed its goals sevenfold, fueling small businesses, creating 1,200+ jobs, and offering a new blueprint for rural revitalization.

Transit-tech firm Argo gets a $1.4M boost from TheVentureCity, a fund led by a former Facebook colleague of Argo's CEO, to scale its smart city solutions.

The robotics firm is outsourcing key software development in a strategic move to reduce cash burn and speed its innovative surgical system to market.

After eliminating over $10.7M in debt, cannabis operator LEEF Brands leverages strong Q3 growth to fuel major expansion in California and New York.

A private tender offer values diagnostics firm PathoCare at $1.75B. Can its AI-powered, non-invasive technology justify the price and transform medicine?

After resolving a cease trade order, A.I.S. Resources is set to resume trading, putting its diverse gold and lithium projects back in the market spotlight.

With a novel therapy from newborn heart cells, Secretome Therapeutics heads to J.P. Morgan to showcase its progress against intractable heart failure.

With promising survival data and a pivotal Phase 3 trial underway, Imunon's localized immunotherapy could finally change the game for ovarian cancer.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

A successful demonstration of Revoltz's compact electric cargo vehicle to Israeli officials could signal a major shift in last-mile logistics.